本文選題：艾滋病病毒I型感染者/艾滋病患者 + 調(diào)節(jié)性B細(xì)胞��； 參考：《大理大學(xué)》2017年碩士論文

【摘要】：目的:本研究旨在觀察調(diào)節(jié)性B細(xì)胞在HIV-1/AIDS患者外周血中的變化,探討其在HIV-1/AIDS疾病中的發(fā)病機(jī)制和疾病發(fā)展進(jìn)程中的作用。研究方法:本項(xiàng)研究以云南省傳染病�？漆t(yī)院住院部和門診部的HIV-1/AIDS患者為實(shí)驗(yàn)組,以醫(yī)療衛(wèi)生工作者和健康體檢人群為對(duì)照組。選擇121例未經(jīng)過(guò)抗病毒治療的HIV-1/AIDS患者,分成兩組,其中無(wú)癥狀感染者82人、艾滋病患者39例,接受HAART治療并長(zhǎng)期隨訪者30例(在121例HIV-1/AIDS患者中選擇)。用流式細(xì)胞術(shù)(FCM)檢測(cè)其外周血中CD1d hiCD5+CD19+B細(xì)胞的比例、CD4+T淋巴細(xì)胞數(shù)量、CD8+T淋巴細(xì)胞數(shù)量、CD4細(xì)胞/CD8細(xì)胞的比值,并與同期選擇的36例健康對(duì)照者作比較。通過(guò)研究HIV-1/AIDS患者和健康對(duì)照者橫斷面隊(duì)列外周血中T淋巴細(xì)胞數(shù)量和調(diào)節(jié)性B細(xì)胞比例變化,以及其中的30例HIV-1/AIDS患者在接受HAART前、后不同時(shí)期T淋巴細(xì)胞數(shù)量和Bergs比例的表達(dá)水平變化,并且觀察30例HIV-1/AIDS患者接受HAART長(zhǎng)期隨訪過(guò)程中艾滋病的縱向進(jìn)展和抗病毒治療療效的關(guān)系,統(tǒng)計(jì)分析組內(nèi)各變量間的相關(guān)性。結(jié)果:HIV-1/AIDS患者外周血中CD4細(xì)胞數(shù)量顯著低于健康對(duì)照組(P0.001),AIDS病人的CD4細(xì)胞數(shù)量顯著低于HIV-1感染組(P0.001)。HIV-1/AIDS患者外周血中CD8細(xì)胞數(shù)量顯著低于健康對(duì)照組(P0.001),而AIDS病人的CD8細(xì)胞數(shù)量與HIV-1感染者相比無(wú)顯著差異(P=0.709)。HIV-1/AIDS患者外周血中CD4細(xì)胞/CD8細(xì)胞比值顯著低于健康對(duì)照組(P0.001),AIDS病人的CD4細(xì)胞/CD8細(xì)胞比值顯著低于HIV-1感染者(P0.001)。HIV-1/AIDS患者外周血中CD1d hiCD5+CD19+B細(xì)胞的比例顯著高于健康對(duì)照組(P0.01),AIDS患者的外周血中的CD1d hiCD5+CD19+B細(xì)胞的比例顯著高于HIV-1感染者(P0.001)。并且HIV-1/AIDS患者外周血中CD1d hiCD5+CD19+B細(xì)胞的比例與CD4細(xì)胞數(shù)量(r=-0.732,r2=0.536,P0.001)和CD8細(xì)胞數(shù)量(r=-0.253,r2=0.064,P=0.011)均呈負(fù)相關(guān)關(guān)系,或者與CD4細(xì)胞/CD8細(xì)胞的比值(r=-0.643,r2=0.414,P0.001)呈負(fù)相關(guān)關(guān)系。30例接受HAART患者在治療前、治療后的2周、1個(gè)月、2個(gè)月、3個(gè)月、6個(gè)月CD1d hiCD5+CD19+B細(xì)胞的比例均與同時(shí)期的CD4細(xì)胞數(shù)量、CD8細(xì)胞數(shù)量呈負(fù)相關(guān)關(guān)系,并且在HAART治療后CD4細(xì)胞均值有上升趨勢(shì),CD1d hiCD5+CD19+B細(xì)胞比例均值有下降趨勢(shì)。結(jié)論:HIV-1/AIDS患者外周血中CD1d hiCD5+CD19+B細(xì)胞顯著升高,并隨著艾滋病的進(jìn)展而明顯增加,經(jīng)過(guò)抗病毒治療后下降。CD1d hiCD5+CD19+B細(xì)胞可能在艾滋病的免疫衰竭中發(fā)揮作用,促進(jìn)了艾滋病的發(fā)展進(jìn)程;針對(duì)性降低HIV-1/AIDS患者的CD1d hiCD5+CD19+B細(xì)胞比例可能有利于抑制艾滋病的發(fā)展進(jìn)程。
[Abstract]:Aim: to observe the changes of regulatory B cells in peripheral blood of patients with HIV-1/AIDS, and to explore the role of B cells in the pathogenesis and progression of HIV-1/AIDS disease. Methods: in this study, the HIV-1/AIDS patients in the inpatient and outpatient departments of Yunnan Provincial Infectious Diseases Hospital were taken as the experimental group, and the medical and health workers and the healthy people as the control group. One hundred and twenty-one patients with HIV-1/AIDS without antiviral therapy were divided into two groups: 82 asymptomatic infection patients, 39 AIDS patients, and 30 patients who received HAART treatment and long-term follow-up (selected from 121 HIV-1/AIDS patients). The ratio of CD1d hiCD5 CD19 B cells in peripheral blood and the ratio of CD4 T lymphocytes to CD8 T lymphocytes and the ratio of CD4 / CD8 cells to CD4 / CD8 cells in peripheral blood were determined by flow cytometry (FCM) and compared with 36 healthy controls selected at the same time. The changes of T lymphocyte count and regulatory B cell ratio in peripheral blood of patients with HIV-1/AIDS and healthy controls were studied, and 30 patients with HIV-1/AIDS were treated with HAART. The expression level of T lymphocytes and Bergs ratio in 30 patients with HIV-1/AIDS were observed during the long term follow-up with HAART. The relationship between the longitudinal progression of AIDS and the efficacy of antiviral therapy was observed. The correlation between the variables in the statistical analysis group. Results the number of CD4 cells in the peripheral blood of patients with HIV / AIDS was significantly lower than that of the healthy control group (P 0.001). The number of CD8 cells in the peripheral blood of patients with HIV 1 / AIDS was significantly lower than that of the patients with HIV-1 infection. The number of CD8 cells in the peripheral blood of patients with HIV / AIDS was significantly lower than that of the healthy control group (P 0.001), while the number of CD8 cells in AIDS patients was significantly lower than that in the patients with HIV-1 infection. The ratio of CD4 cell / CD8 cell in peripheral blood of HIV / AIDS patients was significantly lower than that of the healthy control group (P 0.001). The ratio of CD4 cell / CD8 cell was significantly lower than that of HIV-1 infected patients (P 0.001n. HIV-1 / AIDS). The ratio of CD1d hiCD5 CD19 B in peripheral blood of HIV / AIDS patients with HIV / AIDS was significantly lower than that of patients with HIV / AIDS. The percentage of CD1d hiCD5 CD19 B cells in peripheral blood of P0.01AIDS-infected patients was significantly higher than that of P0.01AIDS-infected patients with HIV-1. Moreover, the ratio of CD1d hiCD5 CD19 B cells in peripheral blood of HIV-1/AIDS patients was negatively correlated with the number of CD4 cells and the number of CD8 cells, respectively. There was a negative correlation between the percentage of CD1d hiCD5 CD19 B cells in peripheral blood and the number of CD4 cells in patients with HIV-1/AIDS, or with the ratio of CD4 cells to CD8 / T cells, r-0.643r2r20.4414P0.001). 30 patients received HAART before the treatment, and 30 patients received HAART before the treatment, and the ratio of CD4 cells to CD8 / T cells was negatively correlated with the ratio of CD4 cells to CD8 / T cells (r -0.643r2tir _ (0.414) P _ (0.001). At 2 weeks, 1 month, 2 months, 3 months, 6 months after treatment, the proportion of CD1d hiCD5 CD19 B cells was negatively correlated with the number of CD4 cells and CD8 cells in the same period. After HAART treatment, the mean value of CD4 cells increased and the ratio of CD1d hiCD5 CD19 B cells decreased. Conclusion CD1d hiCD5 CD19 B cells in the peripheral blood of HIV / AIDS patients were significantly increased and increased with the progression of HIV / AIDS. After antiviral therapy, CD1d hiCD5 CD19 B cells may play a role in the immune failure of AIDS. It can promote the development of AIDS and reduce the proportion of CD1d hiCD5 CD19 B cells in HIV-1/AIDS patients.
【學(xué)位授予單位】：大理大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R512.91

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王強(qiáng);李晶;房俊;;B細(xì)胞及永生B細(xì)胞在傳染性單核細(xì)胞增多癥患兒中的動(dòng)態(tài)變化[J];實(shí)用兒科臨床雜志;2008年22期

2 林東方;張文;趙巖;;B細(xì)胞在原發(fā)性干燥綜合征中的作用[J];中華臨床免疫和變態(tài)反應(yīng)雜志;2009年03期

3 葉向軍;彭來(lái)君;施麗華;;不典型B細(xì)胞幼淋巴細(xì)胞白血病1例[J];臨床血液學(xué)雜志;2010年05期

4 劉克洲;;傳染性單核細(xì)胞增多癥周圍血中的T和B細(xì)胞[J];國(guó)外醫(yī)學(xué)參考資料(流行病學(xué)傳染病學(xué)分冊(cè));1975年01期

5 金天如;;傳染性單核細(xì)胞增多癥患者的B細(xì)胞減少癥[J];國(guó)外醫(yī)學(xué)(免疫學(xué)分冊(cè));1982年06期

6 張鐘儒;;用抗胸腺細(xì)胞球蛋白治療B細(xì)胞慢性淋巴細(xì)胞性白血病骨髓再生不良[J];國(guó)外醫(yī)學(xué)(腫瘤學(xué)分冊(cè));1992年04期

7 姚仁南;腫瘤壞死因子和淋巴細(xì)胞毒素對(duì)絲裂原激活的B細(xì)胞慢性淋巴細(xì)胞白血病細(xì)胞的不均一增殖作用[J];國(guó)外醫(yī)學(xué)(輸血及血液學(xué)分冊(cè));1994年01期

8 編輯部;;免疫療法有望治愈復(fù)發(fā)性B細(xì)胞急性淋巴細(xì)胞白血病[J];轉(zhuǎn)化醫(yī)學(xué)雜志;2013年02期

9 于力;汪月增;;非何杰金氏淋巴瘤患者病變組織和外周血克隆性B細(xì)胞測(cè)定的臨床意義[J];中國(guó)人民解放軍軍醫(yī)進(jìn)修學(xué)院學(xué)報(bào);1991年01期

10 勇威本;;B細(xì)胞慢性淋巴細(xì)胞白血病/小淋巴細(xì)胞淋巴瘤治療現(xiàn)狀[J];世界臨床藥物;2008年08期

相關(guān)會(huì)議論文 前10條

1 吳銘;孫雄飛;徐肇明;張新友;陳曉琳;林海清;文鴻光;孫璇;宋通微;李富榮;王興根;;基于細(xì)胞表型異常的流式細(xì)胞術(shù)檢測(cè)急性前體B細(xì)胞白血病微小殘留病[A];中華醫(yī)學(xué)會(huì)第八次全國(guó)血液學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2004年

2 趙陽(yáng);張風(fēng)肖;;可溶性B細(xì)胞激活因子在原發(fā)性干燥綜合征的表達(dá)及其在致病中作用的研究[A];第17次全國(guó)風(fēng)濕病學(xué)學(xué)術(shù)會(huì)議論文集[C];2012年

3 徐衛(wèi);易樹華;李建勇;邱錄貴;;中國(guó)B細(xì)胞慢性淋巴增殖性疾病診斷專家共識(shí)(2013版)[A];中國(guó)腫瘤內(nèi)科進(jìn)展 中國(guó)腫瘤醫(yī)師教育（2014）[C];2014年

4 黃前榮;高曉明;;鈣網(wǎng)蛋白活化B細(xì)胞的分子機(jī)制研究[A];第六屆全國(guó)免疫學(xué)學(xué)術(shù)大會(huì)論文集[C];2008年

5 雷中勁;張軍紅;;B細(xì)胞激活因子在ITP患兒中表達(dá)的變化與意義[A];中華醫(yī)學(xué)會(huì)第十七次全國(guó)兒科學(xué)術(shù)大會(huì)論文匯編（下冊(cè)）[C];2012年

6 石群立;安曉靜;張正祥;馬捷;汪春年;;T淋巴母細(xì)胞淋巴瘤異常表達(dá)B細(xì)胞相關(guān)抗體-CD79a[A];第十一屆中國(guó)抗癌協(xié)會(huì)全國(guó)淋巴瘤學(xué)術(shù)大會(huì)教育論文集[C];2009年

7 郭穎P，

本文編號(hào)：1902822